A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Futuximab/modotuximab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck KGaA
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 23 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016.
- 07 Aug 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.